Skip to main content Back to Top
Advertisement

11/25/2019

Vincristine Sulfate Injection

Products Affected - Description

    • Vincristine injection, Pfizer, 1 mg/mL, 1 mL vial, 1 count, NDC 61703-0309-06
    • Vincristine injection, Pfizer, 1 mg/mL, 2 mL vial, 1 count, NDC 61703-0309-16

Reason for the Shortage

    • Pfizer has vincristine on shortage due to manufacturing delays and increased demand. They are the sole supplier of vincristine sulfate injection. There is a Dear Healthcare Professional letter available at https://www.fda.gov/media/131865/download.
    • Teva discontinued Vincosar in early-July 2019.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Pfizer has vincristine 1 mg/mL 1 mL and 2 mL vials available in limited supply.

Updated

Updated November 25, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created October 1, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins